A primary oseltamivir-resistant mutation in influenza hemagglutinin and its implications for antiviral resistance surveillance.

ABSTRACT: Oseltamivir, a neuraminidase (NA) inhibitor, is currently the most widely used antiviral drug for influenza worldwide. The emergence of primary oseltamivir-resistant mutations in NA protein of seasonally circulating viruses has been extensively monitored to evaluate drug efficacy. In addition to primary mutations in NA, mutations in the viral hemagglutinin (HA) protein have been observed to arise alongside NA mutations in previous laboratory selection experiments under neuraminidase inhibitor pressure, such HA mutations have not yet been reported in circulating viruses. Here, we present the experimental evidence that an A(H1N1)pdm09 virus can independently acquire oseltamivir-resistance mutations K130N or K130E in the HA receptor binding site (RBS) during serial passages under drug selecti

SUBMITTER: Zhang L 

PROVIDER: S-EPMC12749811 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature